Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.46 |
| ▸ | RRM1 | P23921 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030507 | 0.93 | CASP2 (0.46) | CASP2SLC6A5NAAADNM1EPHX1 | |
| SCHEMBL12201188 | 0.92 | CASP2 (0.58) | CASP2NAAADNM1EPHX1FAAH | |
| SCHEMBL23606518 | 0.91 | DNM1 (0.44) | CASP2SLC6A5NAAADNM1EPHX1 | |
| SCHEMBL8723696 | 0.88 | SLC6A5 (0.55) | CASP2SLC6A5NAAADNM1EPHX1 | |
| SCHEMBL2027019 | 0.86 | CASP2 (0.51) | CASP2NAAADNM1EPHX1FAAH | |
| SCHEMBL1419654 | 0.86 | CASP2 (0.51) | CASP2NAAADNM1EPHX1FAAH | |
| SCHEMBL1419852 | 0.86 | CASP2 (0.51) | CASP2NAAADNM1EPHX1FAAH | |
| SCHEMBL2029786 | 0.86 | CASP2 (0.51) | CASP2NAAADNM1EPHX1FAAH | |
| SCHEMBL1419475 | 0.86 | CASP2 (0.51) | CASP2NAAADNM1EPHX1FAAH | |
| SCHEMBL1419840 | 0.86 | CASP2 (0.51) | CASP2NAAADNM1EPHX1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | MARINA BIOTECH, INC. (US) | 2011-06-02 | — | — | US | claimed |
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | MARINA BIOTECH, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | MARINA BIOTECH, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2009148955-A2 | MULTI-ARM AMINES AND USES THEREOF | MDRNA, INC (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | SNRPE, SNRPA, ADAR | CASP2 3037/4885SLC6A5 2364/4885NAAA 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.